Amazon Pharmacy has expanded its service offering by launching same‑day delivery for Eli Lilly’s newly approved oral GLP‑1 weight‑loss medication Foundayo. The drug, approved by the FDA on April 1 2026, is now available in nearly 3,000 U.S. cities, with plans to extend coverage to about 4,500 locations by the end of the year.
Foundayo is an oral GLP‑1 that does not require refrigeration, allowing it to be shipped quickly through Amazon’s logistics network. Pricing is tiered: with insurance, patients can pay as little as $1 per day or $25 per month; cash‑pay customers face $5 per day or $149 per month.
The medication is accessible through Amazon Pharmacy’s online platform and at select One Medical kiosks, where patients can pick up the drug minutes after a doctor’s appointment, further enhancing convenience.
By adding Foundayo to its pharmacy portfolio, Amazon is creating a new revenue source through prescription fulfillment and pharmacy‑benefit‑manager relationships, while also strengthening its position in the high‑growth GLP‑1 market projected to reach $185.32 billion by 2033.
Amazon’s strategy to integrate logistics and healthcare is reinforced by its acquisition of One Medical and its history of delivering GLP‑1 drugs since 2021. The partnership with Eli Lilly gives Amazon a competitive edge over incumbents such as Novo Nordisk, whose market share is now under increased pressure from Amazon’s same‑day delivery and kiosk pickup options.
Tanvi Patel, Vice President and General Manager of Amazon Pharmacy, said, “If prescribed, patients may be able to have Foundayo on their doorstep the same day or walk out of their doctor’s office with it in hand.”
Amazon Pharmacy also emphasizes affordability, automatically applying manufacturer‑sponsored coupons that have saved customers over $200 million, with GLP‑1 medications being a significant category for these savings.
The launch signals Amazon’s broader healthcare ambitions, leveraging its logistics network to reduce barriers and improve access to weight‑loss medication, potentially reshaping the competitive landscape in the GLP‑1 market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.